Sexually-transmitted infection (STI) - May 24, 2022
Three crucial tests, One new assay
Three crucial tests, One new assay
Back in January 2022, BD introduced the new BD CTGCTV2 for BD MAX™ System to simultaneously test for Chlamydia trachomatis (CT), Neisseria gonorrhoeae (GC) and Trichomonas vaginalis (TV) in one assay, with one patient sample. These three pathogens represent the most prevalent non-viral sexually-transmitted infections (STIs).
After a 6-month transition, this newly CE marked assay will fully replace the BD MAX™ CT/GC/TV as of end of June in Europe, Middle East and Africa.
Our new assay allows for greater flexibility, performance and diagnostic accuracy in STI testing by:
- Eliminating the pre-warm step used in the BD MAX™ CT/GC/TV assay for a 30-minute shorter time to results
- Requiring 2 gene targets for positive GC results
- Performing male TV testing with urine specimens
In addition, BD has also launched new separated collection device options (swab and urine) validated for use with the BD CTGCTV2 / BD CTGC2 assays and with the BD MAX™ Vaginal Panel (swab only). For an even easier workflow, the new collection devices will be delivered with a pierceable reclosable septum cap and the BD CTGCTV2 for BD MAX™ System remains rack and run compatible with most of the assays available on BD MAX™ System.
Get an exclusive sneak peek at the BD CTGCTV2!